Grupo de Melanoma

Inicio | Investigación e innovación | Programas Científicos | Programa de Oncología Molecular | Grupo de Melanoma

María S. Soengas

Investigadores Científicos

  • Nuria Gago
  • Susana García
  • Mariya London

Becarios Post-doctorales

  • Chao Zhang

Becarios Pre-Doctorales

  • Pablo Casado
  • Guillermo De la Vega
  • Naiara Juan
  • Teresa Martí
  • Thelma Poluha
  • José Antonio Torres

Técnicos de Laboratorio

  • Tonantzin Guadalupe Calvo
  • Marta Contreras
  • Viktor Georgiev
  • Cynthia Mucientes

The main objective of our Group is to identify and validate new drivers and therapeutic targets in melanoma, the most aggressive form of skin cancer. We are particularly interested in mechanisms that, being selectively deregulated in melanoma, may account for the unique ability of this tumour type to bypass immune recognition and generate metastasis already from lesions barely over one millimetre in depth (publications in Nature, Cancer Cell, Nature Cell Biology, Nature Communications, among others). Our laboratory has also reported the first-in-class lymphoreporter (MetAlert) mice for non-invasive imaging of pre-metastatic niches in melanoma (Nature). These systems led to the identification of new mechanisms of immune resistance (Nature Medicine) and the generation of nanoparticle-based treatments (Cancer Cell, EMBO Mol Med), with derivatives now being tested in clinical trials. These studies are performed in the context of large cohorts of patient-associated datasets, with the ultimate goal of defining physiological relevance.

Publicaciones

    SELECT dxsjj_posts.* FROM dxsjj_posts LEFT JOIN dxsjj_postmeta ON ( dxsjj_posts.ID = dxsjj_postmeta.post_id ) LEFT JOIN dxsjj_postmeta AS mt1 ON ( dxsjj_posts.ID = mt1.post_id AND mt1.meta_key = 'factor_impacto' ) LEFT JOIN dxsjj_postmeta AS mt2 ON ( dxsjj_posts.ID = mt2.post_id ) LEFT JOIN dxsjj_postmeta AS mt3 ON ( dxsjj_posts.ID = mt3.post_id ) LEFT JOIN dxsjj_postmeta AS mt4 ON ( dxsjj_posts.ID = mt4.post_id ) WHERE 1=1 AND ( ( dxsjj_postmeta.meta_key = 'factor_impacto' OR mt1.post_id IS NULL ) AND mt2.meta_key = 'autores' AND ( mt3.meta_key = 'id_grupos' AND mt3.meta_value LIKE '{2fd38865eb878071a6d00f1af72b25f09382074d5509d17d25be2242ddb00b1a}50006484{2fd38865eb878071a6d00f1af72b25f09382074d5509d17d25be2242ddb00b1a}' ) AND ( mt4.meta_key = 'anyo' AND CAST(mt4.meta_value AS SIGNED) >= '2020' ) ) AND dxsjj_posts.post_type = 'cnio_publication' AND ((dxsjj_posts.post_status = 'publish')) GROUP BY dxsjj_posts.ID ORDER BY CAST(mt4.meta_value AS SIGNED) DESC, CAST(dxsjj_postmeta.meta_value AS SIGNED) DESC, CAST(mt2.meta_value AS CHAR) ASC

  • López-Gil JC, García-Silva S, Ruiz-Cañas L, Navarro D, Palencia-Campos A, Giráldez-Trujillo A, Earl J, Dorado J, Gómez-López G, Monfort-Vengut A, Alcalá S, Gaida MM, García-Mulero S, Cabezas-Sáinz P, Batres-Ramos S, Barreto E, Sánchez-Tomero P, Vallespinós M, Ambler L, Lin ML, Aicher A, García García de Paredes A, de la Pinta C, Sanjuanbenito A, Ruz-Caracuel I, Rodríguez-Garrote M, Guerra C, Carrato A, de Cárcer G, Sánchez L, Nombela-Arrieta C, Espinet E, Sanchez-Arevalo Lobo VJ, Heeschen C, Sainz B Jr. (2024). The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Gut 73, 1489-1508. Publicación CNIO. Open Access Open Access
  • Abrahamian C, Tang R, Deutsch R, Ouologuem L, Weiden EM, Kudrina V, Blenninger J, Rilling J, Feldmann C, Kuss S, Stepanov Y, Rosato AS, Calvo GT, Soengas MS, Mayr D, Fröhlich T, Gudermann T, Biel M, Wahl-Schott C, Chen CC, Bartel K, Grimm C. (2024). Rab7a is an enhancer of TPC2 activity regulating melanoma progression through modulation of the GSK3β/β-Catenin/MITF-axis. Nat Commun 155, 10008. Publicación CNIO.
  • Quílez C, Bebiano LB, Jones E, Maver U, Meesters L, Parzymies P, Petiot E, Rikken G, Risueño I, Zaidi H, Zidarič T, Bekeschus S, H van den Bogaard E, Caley M, Colley H, López NG, Letsiou S, Marquette C, Maver T, Pereira RF, Tobin DJ, Velasco D. (2024). Targeting the Complexity of In Vitro Skin Models: A Review of Cutting-Edge Developments. J Invest Dermatol 144, 2650-2670. Publicación CNIO.
  • Briukhovetska D, Suarez-Gosalvez J, Voigt C, Markota A, Giannou AD, Schübel M, Jobst J, Zhang T, Dörr J, Märkl F, Majed L, Müller PJ, May P, Gottschlich A, Tokarew N, Lücke J, Oner A, Schwerdtfeger M, Andreu-Sanz D, Grünmeier R, Seifert M, Michaelides S, Hristov M, König LM, Cadilha BL, Mikhaylov O, Anders HJ, Rothenfusser S, Flavell RA, Cerezo-Wallis D, Tejedo C, Soengas MS, Bald T, Huber S, Endres S, Kobold S (2023). T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis.. Immunity 56, 143-161. Publicación CNIO. Open Access Open Access
  • Marine JC, Soengas MS (2022). Cell position matters in tumour development. Nature 604, 248-250. Publicación CNIO.
  • Meçe O, Houbaert D, Sassano ML, Durré T, Maes H, Schaaf M, More S, Ganne M, García-Caballero M, Borri M, Verhoeven J, Agrawal M, Jacobs K, Bergers G, Blacher S, Ghesquière B, Dewerchin M, Swinnen JV, Vinckier S, Soengas MS, Carmeliet P, Noël A, Agostinis P (2022). Lipid droplet degradation by autophagy connects mitochondria metabolism to Prox1-driven expression of lymphatic genes and lymphangiogenesis. Nat Commun 13, 2760. Publicación CNIO. Open Access Open Access
  • Patton EE, Mueller KL, Adams DJ, Anandasabapathy N, Aplin AE, Bertolotto C, Bosenberg M, Ceol CJ, Chi P, Herlyn M, Holmen SL, Karreth FA, Kaufman CK, Khan S, Kobold S, Leucci E, Levy C, Lombard DB, Lund AW, Marie KL, Marine JC, Marais R, McMahon M, Robles-Espinoza CD, Ronai ZA, Samuels Y, Soengas MS, Villanueva J, Weeraratna AT, White RM, Yeh I, Zhu J, Zon LI, Hurlbert MS, Merlino G (2021). Melanoma models for the next generation of therapies. Cancer Cell 39, 610-631. Publicación CNIO. Open Access Open Access
  • Olmeda D, Cerezo-Wallis D, Castellano-Sanz E, García-Silva S, Peinado H, Soengas MS (2021). Physiological models for in vivo imaging and targeting the lymphatic system: Nanoparticles and extracellular vesicles. Adv Drug Deliver Rev 175, 113833. Publicación CNIO.
  • Atkins MB, Curiel-Lewandrowski C, Fisher DE, Swetter SM, Tsao H, Aguirre-Ghiso JA, Soengas MS, Weeraratna AT, Flaherty KT, Herlyn M, Sosman JA, Tawbi HA, Pavlick AC, Cassidy PB, Chandra S, Chapman PB, Daud A, Eroglu Z, Ferris LK, Fox BA, Gerhsenwald JE, Gibney GT, Grossman D, Hanks BA, Hanniford D, Hernando E, Jeter JM, Johnson DB, Khleif SN, Kirkwood JM, Leachman SA, Mays D, Nelson KC, Sondak VK, Sullivan RJ, Merlino G (2021). The State of Melanoma: Emergent Challenges and Opportunities. Clin Cancer Res 27, 2678-2697. Publicación CNIO. Open Access Open Access
  • Olmeda D, Cerezo-Wallis D, Mucientes C, Calvo TG, Cañón E, Alonso-Curbelo D, Ibarz N, Muñoz J, Rodriguez-Peralto JL, Ortiz-Romero P, Ortega S, Soengas MS. (2021). Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO Mol Med 13, e12924. Publicación CNIO. Open Access Open Access
  • Cerezo-Wallis D, Contreras-Alcalde M, Troulé K, Catena X, Mucientes C, Calvo TG, Cañón E, Tejedo C, Pennacchi PC, Hogan S, Kölblinger P, Tejero H, Chen AX, Ibarz N, Graña-Castro O, Martinez L, Muñoz J, Ortiz-Romero P, Rodriguez-Peralto JL, Gómez-López G, Al-Shahrour F, Rabadán R, Levesque MP, Olmeda D, Soengas MS. (2020). Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nat Med 26, 1865-1877. Publicación CNIO.
  • Lund AW, Soengas MS (2020). Lymph: (Fe)rrying Melanoma to Safety. Cancer Cell 38, 446-448. Publicación CNIO.

Subir